<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02177773</url>
  </required_header>
  <id_info>
    <org_study_id>CC#14453</org_study_id>
    <nct_id>NCT02177773</nct_id>
  </id_info>
  <brief_title>GA-69 DOTA-TATE Imaging of Somatostatin R+ Malignancies</brief_title>
  <acronym>DOTA-TOC</acronym>
  <official_title>Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies how well gallium Ga 68-DOTA-TOC positron emission tomography
      (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) works in imaging
      patients with somatostatin receptor positive tumors. Gallium Ga 68-DOTA-TOC binds to
      somatostatin receptor positive tumors and can be seen using a PET scan. A PET scan uses a
      special camera to detect energy given off from gallium Ga 68-DOTA-TOC, to make detailed
      pictures of areas where material accumulates in the body. Diagnostic procedures, such as
      gallium Ga 68-DOTA-TOC PET/CT or PET/MRI, may help find and diagnose somatostatin receptor
      positive tumors and help plan the best treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine if gallium Ga 68-DOTA-TOC (gallium-68 labeled DOTA-TOC) results in the
      delineation of more lesions than with conventional imaging.

      SECONDARY OBJECTIVES:

      I. To determine if the incorporation of gallium (Ga)-68 DOTA-TOC PET/CT into the management
      decision making process results in a change in stage of the patient.

      OUTLINE:

      Patients receive gallium Ga 68-DOTA-TOC intravenously (IV) over 1-2 minutes. Within 55-70
      minutes, patients then undergo a PET/CT scan over 30-40 minutes or a PET/MRI scan over 50
      minutes.

      After completion of study, patients are followed up for 2 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2014</start_date>
  <completion_date type="Actual">May 31, 2017</completion_date>
  <primary_completion_date type="Actual">May 31, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of lesions as determined by gallium Ga 68-DOTA-TOC PET imaging</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>The 5 largest lesions in each of eight body regions (head and neck, mediastinum, lung, liver, pancreas, the remaining abdomen and pelvis, bone and lymph nodes), will be measured by size (short and long axis) as well as standardized uptake value maximum on conventional imaging and the gallium Ga 68-DOTA-TOC PET imaging. Additionally, the confidence that each lesion represents a metastasis will be recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical stage as determined by conventional imaging and re-determined by gallium Ga 68-DOTA-TOC PET imaging</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>All previously acquired imaging studies will be used to compare against the research scans and will constitute conventional imaging.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">394</enrollment>
  <condition>Neuroendocrine Tumor</condition>
  <condition>Paraganglioma</condition>
  <condition>Carcinoid Tumors</condition>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Ga-68 DOTA-TOC PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gallium Ga 68-DOTA-TOC IV over 1-2 minutes. Within 55-70 minutes, patients then undergo a PET/CT scan over 30-40 minutes or a PET/MRI scan over 50 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo gallium Ga 68-DOTA-TOC PET/CT</description>
    <arm_group_label>Ga-68 DOTA-TOC PET/CT</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gallium Ga 68-Edotreotide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Ga-68 DOTA-TOC PET/CT</arm_group_label>
    <other_name>Ga-68 DOTA0-Tyr3-octreotide</other_name>
    <other_name>GALLIUM EDOTREOTIDE GA-68</other_name>
    <other_name>Gallium Ga 68-DOTATOC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Ga-68 DOTA-TOC PET/CT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo gallium Ga 68-DOTA-TOC PET/MRI</description>
    <arm_group_label>Ga-68 DOTA-TOC PET/CT</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>Nuclear Magnetic Resonance Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo gallium Ga 68-DOTA-TOC PET/CT</description>
    <arm_group_label>Ga-68 DOTA-TOC PET/CT</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET SCAN</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo gallium Ga 68-DOTA-TOC PET/MRI</description>
    <arm_group_label>Ga-68 DOTA-TOC PET/CT</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET SCAN</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Known or suspected somatostatin receptor positive tumor such as carcinoid;
             neuroendocrine tumor; neuroblastoma; pheochromocytoma; supporting evidence may include
             MRI, CT, biochemical markers, and or pathology report

          -  Karnofsky performance status of &gt; 50 (or Eastern Cooperative Oncology Group
             [ECOG]/World Health Organization [WHO] equivalent)

          -  Not pregnant; a negative serum pregnancy test is required for all female subjects with
             child-bearing potential

          -  Ability to understand a written informed consent document, and the willingness to sign
             it

        Exclusion Criteria:

          -  Hepatic enzymes 5 times greater than the upper limits of normal

          -  Serum creatinine &gt; 3.0 mg/dL (270 uM/L)

          -  Patients exceeding the weight limitations of the scanner or are not able to enter the
             bore of the PET/CT scanner due to body mass index (BMI)

          -  Inability to lie still for the entire imaging time (e.g. cough, severe arthritis,
             etc.); although at Mission Bay Hospital pediatric patients may be sedated per clinical
             protocol

          -  Inability to complete the needed investigational and standard-of-care imaging
             examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)

          -  Any additional medical condition, serious intercurrent illness, or other extenuating
             circumstance that, in the opinion of the investigator, may significantly interfere
             with study compliance

          -  Recognized concurrent active infection

          -  Previous systemic or radiation treatment for another cancer of any type within the
             last 2 months

          -  Use of any other investigational product or device within 30 days prior to dosing, or
             known requirement for any other investigational agent prior to completion of all
             scheduled study assessments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas A Hope, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Imaging Center at China Basin</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Mount Zion</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Mission Bay</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2014</study_first_submitted>
  <study_first_submitted_qc>June 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2014</study_first_posted>
  <last_update_submitted>November 16, 2017</last_update_submitted>
  <last_update_submitted_qc>November 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Thomas Hope</investigator_full_name>
    <investigator_title>Assistant Professor of Radiology and Biomedical Engineering</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Paraganglioma</mesh_term>
    <mesh_term>Carotid Body Tumor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Somatostatin</mesh_term>
    <mesh_term>Edotreotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

